EUROIMMUN AG · Seekamp 31 · 23560 Lübeck (Germany) · Tel +49 451/ 20 32-0 · Fax 20 32-100 · info@euroimmun.de · www.euroimmun.com

Application of EUROIMMUN tests

for COVID-19 diagnostics

Identifi cation of an acute infection by direct virus detection by PCR: EURORealTime SARS-CoV-2

Further monitoring of patients with acute infection (confi rmed by positive PCR): Antibody detection using the Anti-SARS-CoV-2 ELISA (IgA)

Detection of a past contact with the pathogen (from 2 to 4 weeks after infection): Antibody detection using the Anti-SARS-CoV-2 ELISA (IgG)

Correct application of our tests

* IgG seroconversion may take place at different time points after contact with the pathogen (Wölfel R et al. Nature 2020 (Epub) und Obka et al. medRxiv 2020 (preprint))

Meth

od

sC

ou

rse

Sym

pto

ms

Vir

us c

on

tact

Infectious phase Supposed immunity

Cough

Sneezing

Stuffy nose

Sore throat

Fever

Time in days> 1414121086420– 6 – 2– 4

> 1414121086420– 2– 4– 6

Viral load

IgA

Time in days

IgG *

Direct detection

Serology

Anti-SARS-CoV-2ELISA (IgG)

Anti-SARS-CoV-2ELISA (IgA)

EURORealTime SARS-CoV-2

EUROIMMUN AG · Seekamp 31 · 23560 Lübeck (Germany) · Tel +49 451/ 20 32-0 · Fax 20 32-100 · info@euroimmun.de · www.euroimmun.comYI_2606_I_UK_B01, 04/2020

Areas of application of EUROIMMUN SARS-CoV-2 tests

Interpretation of SARS-CoV-2 test results

Characteristics of EUROIMMUN SARS-CoV-2 tests

EURORealTime

SARS-CoV-2

Anti-SARS-CoV-2

ELISA (IgA)

Anti-SARS-CoV-2

ELISA (IgG)

Detection of acute infection

Screening for detection of acute

infections

Detection of pathogen contact

(up to day 10)

Detection of pathogen contact

(from week 2 to 4)

Further monitoring after acute

infection (confi rmed by positive

PCR result)

Detection of past infections

EURORealTime

SARS-CoV-2

Anti-SARS-CoV-2

ELISA (IgA)

Anti-SARS-CoV-2

ELISA (IgG)

Early phase of acute infection

(up to day 10)

Late phase of acute infection

(from day 10)( ) ( ) /

Recent infection ( )

Past infection /

No statement possible

Anti-SARS-CoV-2 ELISA

IgG: High specifi city of 99 % * due to the use of the spike protein domain S1, which is hardly conserved within the coronavirus family; suitable for identifi cation of persons who had contact with the virus some time ago

IgA: Supportive analysis of follow-up samples after infection confi rmed by PCR; indicates a beginning immune reaction; not recommended for screening because of a limited specifi city of approx. 90 % in reference cohorts

EURORealTime SARS-CoV-2

High sensitivity and reliability due to simultaneous detection of two target sequences of SARS-CoV-2

Only one reaction per sample

* in various donor cohorts (samples taken before the outbreak of the COVID-19 pandemic), including blood donors, pregnant women, persons with vaccinations, bacterial or viral infections or autoimmune diseases